Loading…

Hanmi Pharmaceutical shares rose more than 6% on November 20 after reports that the initial supply of its domestically developed obesity drug Epe, worth about KRW 10 billion, sold out ahead of expectations. The gain came during a sharp broader sell-off in which the KOSPI and KOSDAQ fell more than 5% intraday.
This is a pharmaceutical equity story with no direct link to feed grains, oilseeds, or animal-feed ingredient supply or prices.
Not enough comparable past events yet for a historical read.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.